News
-
09.02.2010
Debiopharm Group™ grants an exclusive licence for the development, manufacture and commercialisation of Debio 025 - A potent, first-in-class antiviral agent for the treatment of Hepatitis C - -
04.02.2010
Launch of Ipsen’s Decapeptyl® 6-month formulation (LP 22.5 mg) in France for the treatment of locally advanced or metastatic hormone-dependent prostate cancer
Conferences
| During the year, Debiopharm Group will be present at selected events, such as scientific roundtables, conferences, presentations etc.
| ||||||||||||||||
| ||||||||||||||||
| ||||||||||||||||
| < Prev 1 2 Next > | ||||||||||||||||
| Results 1 - 5 of 7 | ||||||||||||||||



